Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2019 Jul 26;121(5):429–430. doi: 10.1038/s41416-019-0528-0

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Vera Gorbunova 1, J Thaddeus Beck 2, Ralf-Dieter Hofheinz 3, Pilar Garcia-Alfonso 4, Marina Nechaeva 5, Antonio Cubillo Gracian 6, Laszlo Mangel 7, Elena Elez Fernandez 8, Dustin A Deming 9, Ramesh K Ramanathan 10, Alison H Torres 11, Danielle Sullivan 11, Yan Luo 11, Jordan D Berlin 12,
PMCID: PMC6738103  PMID: 31350526

Correction to: British Journal of Cancer (2019) 120, 183–189; 10.1038/s41416-018-0343-z; published online 11 December 2018

The original version of this article contained an error in Fig. 1a. The number of patients at risk listed in the Veliparib arm of Fig. 1a should have read “65” instead of “35”. The correct figure is below.

Fig. 1.

Fig. 1

a Progression-free survival at final analysis and b overall survival at final analysis. CI confidence interval, PBO placebo + FOLFIRI ± bevacizumab, VEL veliparib + FOLFIRI ± bevacizumab


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES